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A B S T R A C T 
Platinum  based  doublet  chemotherapy  namely  the  cisplatin/carboplatin  based  etopiside  or  gemcitabine  therapy 
forms the therapy of choice, for patients with advanced non small cell carcinoma of the lung. Here we report two 
cases  were  unusual  cross  over  was  done  from  gemcitabine-to  cisplatin-doublet  chemotherapy  resulting  in 
unexpectedly better clinical and radiological response. 
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Introduction 
Lung  cancer  is  the  leading  cause  of  cancer  related 
mortality  in  both  men  and  women  throughout  the 
world. In 2007, an estimated 1.5 million new cases of 
lung cancer were diagnosed globally, accounting for 
approximately 12% of the global cancer burden
1. The 
treatment  of  NSCLC  is  surgery  for  early  stages, 
chemotherapy  with  concurrent  radiation  for  locally 
advanced  cancers,  and  palliative  chemotherapy  for 
metastatic  disease 
2.  Cisplatin  based  doublet 
(Gemcitabine  /Etoposide)  chemotherapy  is  the 
treatment of choice, and, cisplatin plus Gemcitabine 
doublet having the better toxicity   profile 
3. We are 
reporting  here  our  experience  with  two  patients  in 
whom  we  were  forced  to  switch  over  from 
Gemcitabine  –to  -Cisplatin  doublet  regimen  due  to 
interruption  of  supply  of  Gemcitabine  from  our 
hospital.  
 
Case  1:  A 40 -year- old ex-smoker presented  with 
complaints of dry cough, chest pain and hemoptysis 
of 3 months duration. Chest X ray PA view revealed 
homogeneous  opacity  in  left  upper  and  midzone 
(Figure 1a), and CT Thorax showed attenuated lesion 
measuring 6.5x5x3 cm in the apico-posterior segment 
of  left  upper  lobe(Figure  1b).CT  guided  biopsy  of  
the lesion was done and its histopathology revealed 
TTF 1 positive adenocarcinoma. Thus the patient was 
diagnosed  to  have  bronchogenic  carcinoma  type 
adeno and the TNM staging was III B T4 N2M0. His 
Karnofsky  performance  status  score  was  60  and 
ECOG score was 2. He was started on Gemcitabine 
(1250mg  /m
2)  plus  Cisplatin  (100mg/m
2)  regimen. 
After two cycles we were forced to switch over to 
cisplatin plus etoposide. Patient then completed four 
cycles  of  Cisplatin  and  etoposide  (30  mg/m
2).  On 
completion  of  six  cycles  there  was  dramatic 
radiological  (Figure  1c)  and  clinical  response  with 
karnofsky of 90 and ECOG of 0.   
 
Case 2: A 60 –year old smoker and alcoholic patient 
was admitted in our department with complaints of  
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hemoptysis  of  one  month  duration.  His  admission 
chest  radiograph  revealed  prominent  left  hilum 
(Figure 2a) and CT Thorax showed nodular lesion in 
superior  segment  of  left  lower  lobe  (Figure  2b). 
Bronchoscopy  was  done  and  transbronchial  lung 
biopsy  from  superior  segment  of  left  lower  lobe 
revealed squamous cell carcinoma. Thus the patient 
was diagnosed to have bronchogenic carcinoma type 
squamous with TNM  staging of  III A T2N2M0 .His 
Karnofsky  performance  Status  score  was  40  and 
ECOG  score  was  3.He  was  planned  concurrent 
chemo-radiotherapy  followed  by  surgical  resection, 
but he refused both radiotherapy and surgery , and 
was  put  on  Gemcitabine(1250mg/m
2)  and 
Cisplatin(120mg/m
2) therapy. Just like our previous 
patient, after two cycles we were forced to shift over 
to  etoposide  (50  mg/m
2)  from  Gemcitabine.  On 
completion of six cycles he also showed good clinical 
recovery (Figure 2c) with karnofsky of 80 and ECOG 
of 1. 
 
Figure 1:Intial chest skiagram (a) showing homogeneous nodular opacity in left upper and midzones ,admission 
computed tomography(b) showing rounded soft tissue attenuated lesion measuring 6.5×5×3 cm in the left apico-
posterior and postchemotherapy one(c) revealing thick walled cavity with adjacent fibrosis in the same segment. 
 
 
 
Figure 2: Admission chest x ray (a) showing prominent left hilum (arrow), computed tomography (b) revealing 
4.4×4×3 cm nodular lesion in superior segment of left lower lobe (arrow) and post six cycles computed tomography 
depicting (c) residual lesion. 
 
Discussion 
The choice of treatment in a case of   lung cancer 
depends  on  the  type  of  lung  cancer,  the  size  and 
location  of  tumor,  whether  or  not  the  tumour  has 
spread outside the lungs, the patient’s age and general 
health status. Treatment options include radiotherapy, 
chemotherapy  and  surgery.  Newer  treatment 
modalities include targeted therapy, cryosurgery, laser 
surgery,  photodynamic  therapy,  electrocautery  and 
internal  radiation.  Non  Small  Cell  Lung  Cancer 
(NSCLC) with stages I and II are usually treated with 
surgery. In patients with stages I and II were surgery 
can’t  be  done  due  to  poor  lung  reserves  radiation 
therapy  is  used.  Chemotherapeutic  regimens  are 
usually reserved for advanced stages like III and IV 
or as adjuvant therapy, that is, to be used after surgery 
or as neoadjuvant therapy, which is treatment before 
surgery.  
 
Platinum-based  chemotherapeutic  agent  is  the 
standard care of treatment in patients with NSCLC 
especially  in  advanced  disease  (stages  III  and 
especially IV) 
4,5. Combination regimens are usually 
preferred and this often includes a platinum drug like  
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cisplatin along with etoposide or newer agents like 
docetaxel,  gemcitabine,  pemetrexed  or 
vinorelbine
5 .Even after extensive search in pub med 
database  we  were  unable  to  find  any  literature  on 
gemcitabine-to  cisplatin-doublet  cross  over 
chemotherapy. But is this just a matter of chance or is 
it  really  a  method  worth  following,  needs  to  be 
evaluated  on  large  scale  by  further  randomised 
studies,  which  will  be  a  real  boon  for  the  already 
ailing cancer patient and their families. 
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